{"id":965795,"date":"2026-05-21T08:06:45","date_gmt":"2026-05-21T12:06:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\/"},"modified":"2026-05-21T08:06:45","modified_gmt":"2026-05-21T12:06:45","slug":"biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\/","title":{"rendered":"BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency"},"content":{"rendered":"<div class=\"mw_release\">\n<p>\n        <strong><br \/>\n          <em>\u2013 Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory angina and validate continued clinical development<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong><br \/>\n          <em>\u2013 Novel therapeutic approach targets a critically important unmet medical need for patients who have debilitated quality-of-life and have exhausted all available treatment options <\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>SUNNYVALE, Calif., May  21, 2026  (GLOBE NEWSWIRE) &#8212; BioCardia, Inc. (NASDAQ: BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the oral presentation of the results of the CardiAMP<sup>\u00ae<\/sup>\u00a0Cell Therapy in Chronic Myocardial Ischemia Trial (CardiAMP CMI) preliminary open label cohort at EuroPCR, a leading interventional cardiovascular medicine conference held in Paris. The presentation was made by Dr. Amish Raval, M.D., Professor of Medicine at University of Wisconsin School of Medicine and Public Health.<\/p>\n<p>Results presented by Dr. Raval, on behalf of the CardiAMP CMI Investigators, showed that the minimally invasive CardiAMP Cell Therapy procedure was well tolerated with no treatment emergent major adverse cardiac events and patients demonstrated positive clinical outcomes including increased exercise tolerance and reduced frequency of angina episodes with the autologous cell therapy up through 2 years follow-up. Prior to treatment, all patients were on guideline-directed medical therapy (GDMT) and had received all available percutaneous and\/or surgical options as appropriate for their medical condition. Patients experienced increased exercise tolerance, improving by an average of 179 seconds, which persisted for the two-year study follow-up. Angina episodes were reduced by an average of 82% by six-months after treatment. Dr. Raval\u2019s presentation is here:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ge9kzSRuMqSlfOcNxzjgk5Q13H3BW_G86ItUhdLYoMDMVl-D333uUrxbkvdmGYWFCuVUguWcMNFpZv-9AQ_1UEnJ85ykOw94yAl_EIIWDQU5a_nzsxwCwnz9qC_KK5PsYKjjQrL-TdVP9lqQAiOrz53uX1IyzWETowGo4CT4P8s=\" rel=\"nofollow\" target=\"_blank\">EuroPCR2026<\/a>.<\/p>\n<p>\u201cChronic ischemic heart disease results in considerable limitations of daily life activities due to chest discomfort, shortness of breath, and related disabling symptoms despite optimal medical therapy,\u201d said Carl Pepine, MD, MACC, Professor of Medicine, Division of Cardiovascular Medicine, University of Florida at Gainesville. \u201cA cell-based approach, added to this medical therapy, has potential to better manage these symptoms and improve the quality of life.\u201d\u00a0<\/p>\n<p>\u201cWe are thankful for the physician scientists who contributed their great experience to this program as well as the patients who participated,\u201d said Peter Altman, PhD, BioCardia President and CEO. \u201cThese results support this CardiAMP cell therapy approach which has potential to help patients suffering from refractory angina. To our knowledge, only cell therapy has had a positive impact on both exercise tolerance and angina episodes in these patients.\u201d<\/p>\n<p>\n        <strong>About Chronic Myocardial Ischemia with Refractory Angina<\/strong>\n      <\/p>\n<p>Chronic myocardial ischemia occurs in the setting of coronary artery disease when there is reduced blood flow to the heart. This causes angina, a type of chest pain which is characterized as refractory angina when this pain cannot be controlled by a combination of optimal medical therapy, angioplasty or bypass surgery, and is estimated to impact 600,000 to 1.8 million patients in the United States. Up to 15% of patients who have ischemia or angina and undergo cardiac catheterization are suboptimal candidates for conventional revascularization. Although prognosis of refractory angina has improved in recent years, patients with refractory angina experience a significantly impaired quality of life with disproportionately high utilization of healthcare services. These observations reflect the great need for new therapies for these patients.<\/p>\n<p>\u00a0<strong>About the CardiAMP Cell Therapy Program<\/strong><\/p>\n<p>Designated by the FDA as a Breakthrough Therapy for Ischemic Heart Failure, CardiAMP Cell Therapy uses a patient\u2019s own bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body\u2019s natural healing response.\u00a0CardiAMP Cell Therapy incorporates three proprietary elements not previously utilized in investigational cardiac cell therapy: a pre-procedural cell analysis for patient selection, a high target dosage of cells, and a proprietary delivery system that has been shown to be safer than other intramyocardial delivery systems and exponentially more successful in cell retention. The CardiAMP cell therapy trials for the indications of both chronic myocardial ischemia and ischemic heart failure are covered by the Center for Medicare and Medicaid for both treatment and control procedures.\u00a0 CAUTION &#8211; Limited by United States law to investigational use.\u00a0<\/p>\n<p>\n        <strong>About BioCardia<sup>\u00ae<\/sup>\u00a0<\/strong>BioCardia, Inc.,\u00a0headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP<sup>\u00ae<\/sup> autologous and CardiALLO\u2122 allogeneic cell therapies are the Company\u2019s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix\u2122 biotherapeutic delivery and Morph<sup>\u00ae<\/sup> vascular navigation product platforms, and soon the Heart3D\u2122 fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biologic therapies.\u00a0 For more information visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vb5-cqiFmFszuTN7X51XRetF_Q6lzbZmZee-ucsNC6QX4TWdn5RAI0BvUmT1oHK3KhVctao4riSj8qh4Wfrszwj1UHD0yJhYa-tOg9UiDZE=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.biocardia.com<\/a>.<\/p>\n<p>\n        <strong>Forward Looking Statements:<\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements may include, among other things, statements relating to the continued development, ability to offset clinical costs utilizing Medicare reimbursement and the ultimate success of our clinical cell therapy programs. These forward-looking statements are made as of the date of this press release.<\/p>\n<p>We may use terms such as \u201cbelieves,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201capproximately\u201d or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. Factors that could cause or contribute to such differences include, but are not limited to, the Company\u2019s liquidity position and its ability to raise additional funds, as well as the Company\u2019s ability to successfully advance its clinical trials. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia\u2019s Form 10-K filed with the Securities and Exchange Commission on March 24, 2026, under the caption titled \u201cRisk Factors,\u201d and in our subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.<\/p>\n<p>\n        <strong>Media Contact: <\/strong><br \/>\n        <br \/>Miranda Peto, Investor Relations<br \/>Email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Dz3I1iTPqJQovYhQFv9slSJwTDSkuyAPUz-ZcxVoxRxdaPRwoJ8I1gcHbWCJaPBPraj59qo12zpL5S8zKYhYAH2t2HLAKvbZP2uDJoDXlH8=\" rel=\"nofollow\" target=\"_blank\">mpeto@BioCardia.com<\/a><br \/>Phone: 650-226-0120<\/p>\n<p>\n        <strong>Investor Contact: <\/strong><br \/>\n        <br \/>David McClung, Chief Financial Officer<br \/>Email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LRhbVQGtZUY5opivOrrwOcXQpcJ7LQbDkS693Uq3WlE2hLhoihBXB5NT-mi3ejuoGibtOj3i5a0ZiEdEN8zoq8iZa0mISXzwPg6IhOapDM16mha97HrWZL0Oj__D2i05\" rel=\"nofollow\" target=\"_blank\">investors@BioCardia.com<\/a><br \/>Phone: 650-226-0120<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDM3MiM3NjE0ODE5IzIwMTk4MTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YzMyYTYwMjAtOGU4Ni00MmU4LWFmZjYtZTIwMmQ3MWYyZDBkLTEwMzEzOTEtMjAyNi0wNS0yMS1lbg==\/tiny\/BioCardia-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2013 Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory angina and validate continued clinical development \u2013 Novel therapeutic approach targets a critically important unmet medical need for patients who have debilitated quality-of-life and have exhausted all available treatment options SUNNYVALE, Calif., May 21, 2026 (GLOBE NEWSWIRE) &#8212; BioCardia, Inc. (NASDAQ: BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the oral presentation of the results of the CardiAMP\u00ae\u00a0Cell Therapy in Chronic Myocardial Ischemia Trial (CardiAMP CMI) preliminary open label cohort at EuroPCR, a leading interventional cardiovascular medicine conference held in Paris. The presentation was &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-965795","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2013 Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory angina and validate continued clinical development \u2013 Novel therapeutic approach targets a critically important unmet medical need for patients who have debilitated quality-of-life and have exhausted all available treatment options SUNNYVALE, Calif., May 21, 2026 (GLOBE NEWSWIRE) &#8212; BioCardia, Inc. (NASDAQ: BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the oral presentation of the results of the CardiAMP\u00ae\u00a0Cell Therapy in Chronic Myocardial Ischemia Trial (CardiAMP CMI) preliminary open label cohort at EuroPCR, a leading interventional cardiovascular medicine conference held in Paris. The presentation was &hellip; Continue reading &quot;BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-21T12:06:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDM3MiM3NjE0ODE5IzIwMTk4MTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency\",\"datePublished\":\"2026-05-21T12:06:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\\\/\"},\"wordCount\":1060,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNDM3MiM3NjE0ODE5IzIwMTk4MTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\\\/\",\"name\":\"BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNDM3MiM3NjE0ODE5IzIwMTk4MTk=\",\"datePublished\":\"2026-05-21T12:06:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNDM3MiM3NjE0ODE5IzIwMTk4MTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNDM3MiM3NjE0ODE5IzIwMTk4MTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\/","og_locale":"en_US","og_type":"article","og_title":"BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency - Market Newsdesk","og_description":"\u2013 Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory angina and validate continued clinical development \u2013 Novel therapeutic approach targets a critically important unmet medical need for patients who have debilitated quality-of-life and have exhausted all available treatment options SUNNYVALE, Calif., May 21, 2026 (GLOBE NEWSWIRE) &#8212; BioCardia, Inc. (NASDAQ: BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the oral presentation of the results of the CardiAMP\u00ae\u00a0Cell Therapy in Chronic Myocardial Ischemia Trial (CardiAMP CMI) preliminary open label cohort at EuroPCR, a leading interventional cardiovascular medicine conference held in Paris. The presentation was &hellip; Continue reading \"BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-21T12:06:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDM3MiM3NjE0ODE5IzIwMTk4MTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency","datePublished":"2026-05-21T12:06:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\/"},"wordCount":1060,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDM3MiM3NjE0ODE5IzIwMTk4MTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\/","name":"BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDM3MiM3NjE0ODE5IzIwMTk4MTk=","datePublished":"2026-05-21T12:06:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDM3MiM3NjE0ODE5IzIwMTk4MTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDM3MiM3NjE0ODE5IzIwMTk4MTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/965795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=965795"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/965795\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=965795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=965795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=965795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}